TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9043729

Group type: EXPERIMENTAL
Intervention: 0.4 mg glycopyrrolate im
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.4 mg hyoscine hydrobromide po
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.4 mg hyoscine hydrobromide im
Number of subjects: 80

Group type: COMPARATOR
Intervention: No anticholinergic
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 8936349

Group type: EXPERIMENTAL
Intervention: Extended Disability Status Scale (EDSS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Scripps Neurologic Rating Scale (SNRS)
Number of subjects: 48
Study: 2407084

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg orally 3 times daily (group 1, n = 115)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg orally 3 times daily plus dipyridamole 75 mg orally 3 times daily (group 2, n = 117)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg orally 3 times daily (group 1)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg orally 3 times daily plus dipyridamole 75 mg orally 3 times daily (group 2)
Number of subjects: 232
Study: 7002183

Group type: EXPERIMENTAL
Intervention: Aspirin (250, 500, and 1000 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proquazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluproquazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New formulations of Optalidon (aminopyrine replaced by propyphenazone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New formulations of Tonopan (aminopyrine replaced by propyphenazone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of aminopyrine, caffeine, and butalbarbital (Optalidon)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of aminopyrine, caffeine, butalbarbital, and dihydroergotamine (Tonopan)
Number of subjects: 0
Study: 31724026

Group type: EXPERIMENTAL
Intervention: Fixed-Duration Chemotherapy-Free Treatment
Number of subjects: 0
Study: 28545978

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg injections every 4 weeks for 12 weeks
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 351
Study: 25504861

Group type: COMPARATOR
Intervention: Tocilizumab
Number of subjects: 112
Study: 25140772

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no inhaled nitric oxide)
Number of subjects: 60
Study: 22443353

Group type: EXPERIMENTAL
Intervention: ADIPOR1 SNPs (rs1342387 and rs12733285)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: ADIPOQ SNPs
Number of subjects: 77
Study: 20102872

Group type: EXPERIMENTAL
Intervention: Glycemia levels categorized as < or = 100 mg/dL (5.5 mmol/L)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Patients with diabetes mellitus
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Overall cohort of patients
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Unplanned hospital admission
Number of subjects: 456
Study: 18716704

Group type: EXPERIMENTAL
Intervention: Polypropylene mesh
Number of subjects: 202

Group type: COMPARATOR
Intervention: No mesh
Number of subjects: 202
Study: 16024244

Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 11849660

Group type: EXPERIMENTAL
Intervention: Fluvastatin (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pravastatin (n=20)
Number of subjects: 40
Study: 10065804

Group type: EXPERIMENTAL
Intervention: New parallel technique of Veress needle insertion (group 2; n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional closed method (group 1; n = 100)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: New parallel technique of Veress needle insertion
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional closed method
Number of subjects: 200
Study: 8774014

Group type: EXPERIMENTAL
Intervention: Group I (last two movements reversed)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group II (second two movements reversed)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group III (first two movements reversed)
Number of subjects: 30
Study: 1611640

Group type: EXPERIMENTAL
Intervention: Diltiazem hydrochloride 120 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diltiazem hydrochloride 240 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diltiazem hydrochloride 360 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diltiazem hydrochloride 480 mg
Number of subjects: 12
Study: 6508407

Group type: EXPERIMENTAL
Intervention: Hyperthermic regional cytostatic perfusion with melphalan (42 C)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (wide excision and lymph node dissection)
Number of subjects: 107
Study: 30855449

Group type: EXPERIMENTAL
Intervention: Polaprezinc
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-polaprezinc
Number of subjects: 50
Study: 30584293

Group type: EXPERIMENTAL
Intervention: IND/MF (QMF149) 150/160 µg once daily
Number of subjects: 629

Group type: COMPARATOR
Intervention: Sal/Flu (50/500 µg twice daily)
Number of subjects: 629
Study: 26368280

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH)
Number of subjects: 24
Study: 23352196

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg monthly
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg PRN
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg monthly
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg PRN
Number of subjects: 1098
Study: 21306595

Group type: EXPERIMENTAL
Intervention: Current major depressive episode (MDE) at baseline
Number of subjects: 261

Group type: COMPARATOR
Intervention: Recent (31+ days to 12 months) MDE
Number of subjects: 261

Group type: COMPARATOR
Intervention: Past MDE at baseline
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Current MDE at baseline
Number of subjects: 261
Study: 19290768

Group type: EXPERIMENTAL
Intervention: Linguistic Inquiry and Word Count (LIWC)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Psychiatric Content Analysis and Diagnosis (PCAD)
Number of subjects: 63
Study: 17429201

Group type: EXPERIMENTAL
Intervention: IP Extra (group 1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: IP Standard (group 2)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 31
Study: 15365213

Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acetate-free hemodialysis (AFHD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Bicarbonate dialysis (BD)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All techniques (AFB, AFHD, BD)
Number of subjects: 9
Study: 11276406

Group type: EXPERIMENTAL
Intervention: Antidepressant treatments (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonexperimental evidence of antidepressant use (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive model for assessing antidepressant use in youths
Number of subjects: 0
Study: 8385750

Group type: EXPERIMENTAL
Intervention: Natural conjugates oestrogen (0.625 mg per diem per os) plus MAP (10 mg per diem per os) for 12 days a month
Number of subjects: 28

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 28
Study: 3955441

Group type: EXPERIMENTAL
Intervention: Bilateral medial rectus muscle recession without severing check ligaments
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bilateral medial rectus muscle recession with severing check ligaments
Number of subjects: 25
Study: 29117990

Group type: EXPERIMENTAL
Intervention: Midostaurin (PKC412) administered daily for 4 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midostaurin with ketoconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midostaurin with rifampicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midostaurin with midazolam
Number of subjects: 0
Study: 27638296

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 90
Study: 25274978

Group type: COMPARATOR
Intervention: 9-valent HPV vaccine (HPV6/11/16/18/31/33/45/52/58)
Number of subjects: 12614

Group type: COMPARATOR
Intervention: HPV types (HPV35/39/51/56/59)
Number of subjects: 12614

Group type: EXPERIMENTAL
Intervention: HPV6/11/16/18/31/33/45/52/58
Number of subjects: 12614
Study: 24423823

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin, gemcitabine, paclitaxel, and pemetrexed) under the guidance of molecular markers
Number of subjects: 86

Group type: COMPARATOR
Intervention: Vinorelbine 25 mg/m(2) days 1 and 8 with 21 days as a cycle
Number of subjects: 86
Study: 20227156

Group type: EXPERIMENTAL
Intervention: Two-thumb technique
Number of subjects: 34

Group type: COMPARATOR
Intervention: Two-finger technique
Number of subjects: 34
Study: 18849230

Group type: EXPERIMENTAL
Intervention: Internal thoracic artery preparation with intact pleura (Group 1)
Number of subjects: 54
Study: 16449899

Group type: EXPERIMENTAL
Intervention: Distraction and fusion using Harrington rods (ST)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Brace treatment (BT)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 283
Study: 12865036

Group type: EXPERIMENTAL
Intervention: Key staff turnover in the HT-CT (clinic practitioner, clinic manager, principal investigator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Key staff turnover in the DM-CT (lead nutritionist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Key staff turnover in the DM-CT and HT-CT
Number of subjects: 0
Study: 11042989

Group type: EXPERIMENTAL
Intervention: 15 percent CP whitening agent
Number of subjects: 57

Group type: COMPARATOR
Intervention: 10 percent CP whitening agent
Number of subjects: 57
Study: 8778601

Group type: EXPERIMENTAL
Intervention: Regularly scheduled inhaled albuterol
Number of subjects: 255

Group type: COMPARATOR
Intervention: As-needed inhaled albuterol
Number of subjects: 255
Study: 1462677

Group type: EXPERIMENTAL
Intervention: Beta-carotene (n = 6)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: D-alpha-tocopherol (n = 6)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Selenium (n = 6)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (n = 6)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ultraviolet light exposure (n = 24)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sunbathing (n = 8)
Number of subjects: 54
Study: 2875904

Group type: EXPERIMENTAL
Intervention: Brompheniramine maleate (12 mg twice daily in sustained release form)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg twice daily)
Number of subjects: 16
Study: 31631788

Group type: EXPERIMENTAL
Intervention: Distributed training schedule
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Massed training schedule
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hybrid training schedule 1
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hybrid training schedule 2
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study: 29857773

Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard of care (SOC) smoking cessation services
Number of subjects: 49
Study: 27596557

Group type: EXPERIMENTAL
Intervention: Double-J stent indwelling for 7 days
Number of subjects: 142

Group type: COMPARATOR
Intervention: Double-J stent indwelling for > 7 days
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 142
Study: 24115082

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab 162 mg every 2 weeks (q2w)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab 162 mg weekly (qw)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab 81 mg every 2 weeks (q2w)
Number of subjects: 32
Study: 22152401

Group type: EXPERIMENTAL
Intervention: Supportive-expressive psychotherapy (SET)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy + clinical management (MED)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Pill-placebo + clinical management (PBO)
Number of subjects: 156
Study: 21636321

Group type: EXPERIMENTAL
Intervention: 4-week passive stretching program consisting of 4 hamstring and hip stretches performed 5 times per week
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-stretching control group
Number of subjects: 22
Study: 19797987

Group type: EXPERIMENTAL
Intervention: Anterior subfascial transposition of the ulnar nerve
Number of subjects: 117

Group type: COMPARATOR
Intervention: In situ decompression of the ulnar nerve
Number of subjects: 117
Study: 16951518

Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing model (increasing by 15 beats per minute on the basic rate of the mean nocturnal sinus)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Spontaneous rhythm model
Number of subjects: 16
Study: 15301658

Group type: EXPERIMENTAL
Intervention: Nicotine patch plus bupropion SR (150 mg per day)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Nicotine patch plus placebo
Number of subjects: 211
Study: 12212624

Group type: EXPERIMENTAL
Intervention: Simulated altitude of 2800 m for 1 h
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Simulated altitude of 3600 m for 1 h
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Simulated altitude of 4400 m for 1 h
Number of subjects: 18

Group type: COMPARATOR
Intervention: Simulated altitude of 300 m (control)
Number of subjects: 18
Study: 9349066

Group type: EXPERIMENTAL
Intervention: morphine (75 micrograms.kg‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: buprenorphine (3 micrograms.kg‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: sufentanil (0.2 microgram.kg‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: lignocaine and bupivacaine alone
Number of subjects: 80
Study: 8463436

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3896355

Group type: EXPERIMENTAL
Intervention: Tinnitus maskers
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Combination instruments (masker plus hearing aid)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 472

Group type: COMPARATOR
Intervention: Thorough investigation and careful counselling
Number of subjects: 472

Group type: COMPARATOR
Intervention: Audiometric and tinnitus tests
Number of subjects: 472
Study: 29541962

Group type: EXPERIMENTAL
Intervention: Men in Life Environments (MILE) intervention
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 212
Study: 26829370

Group type: EXPERIMENTAL
Intervention: Weight-neutral program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional weight-management program
Number of subjects: 80
Study: 23891925

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg, twice daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 23062530

Group type: EXPERIMENTAL
Intervention: Exercise training (moderate exercise volumes of 3 to <5 MET-h and 5 to <7 MET-h per week)
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Exercise volume
Number of subjects: 959
Study: 20374562

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/day) for 3 months
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo supplementation for 3 months
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/day) for 9 months
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo supplementation for 9 months
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/day)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 353
Study: 18922495

Group type: EXPERIMENTAL
Intervention: Brand A nonwaterproof mascara
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Brand B nonwaterproof mascara
Number of subjects: 40
Study: 15807218

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 10 mg/day for 10 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 12625969

Group type: EXPERIMENTAL
Intervention: Metronidazole treatment (rectally for at least 4 days)
Number of subjects: 142

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 142
Study: 10520835

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7496647

Group type: EXPERIMENTAL
Intervention: Paroxetine (20, 40, or 60 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1784590

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg.3/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Atropine (increasing boluses)
Number of subjects: 8
Study: 6807568

Group type: EXPERIMENTAL
Intervention: Verapamil, 480 mg/day
Number of subjects: 26
Study: 31072856

Group type: EXPERIMENTAL
Intervention: Psychiatrists' experiences and perspectives on treating DS patients
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Other healthcare professionals' attitudes towards DS
Number of subjects: 10
Study: 28296763

Group type: EXPERIMENTAL
Intervention: 0.5 mg M-001
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 1.0 mg M-001
Number of subjects: 222

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: M-001
Number of subjects: 222
Study: 25715171

Group type: EXPERIMENTAL
Intervention: Naltrexone and clinical case management for 12 weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 24019052

Group type: EXPERIMENTAL
Intervention: Behavioral educational intervention targeting modifiable factors associated with postpartum depressive symptoms
Number of subjects: 540

Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 540
Study: 20935327

Group type: EXPERIMENTAL
Intervention: Cognitive-linguistic treatment (CLT), 6 months, at least 2 hours per week
Number of subjects: 80

Group type: COMPARATOR
Intervention: Communicative treatment, 6 months, at least 2 hours per week
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cognitive-linguistic treatment (CLT)
Number of subjects: 80
Study: 19522781

Group type: EXPERIMENTAL
Intervention: Home-based ecologically based family therapy (EBFT)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Office-based functional family therapy (FFT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Service as usual (SAU)
Number of subjects: 119
Study: 16960264

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with deliberate hypotension (target mean arterial pressure of 55-60 mmHg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (general anesthesia without deliberate hypotension)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with deliberate hypotension
Number of subjects: 102
Study: 15055821

Group type: EXPERIMENTAL
Intervention: 6 months treatment with growth hormone (2 IU/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study: 11218239

Group type: EXPERIMENTAL
Intervention: Growth hormone (mean, 0.12 mg/kg/day) plus oral glutamine (mean, 28 g/day) and parenteral glutamine (mean, 5.2 g/day) for 28 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Growth hormone and glutamine treatment
Number of subjects: 8
Study: 9355019

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (AT) for 18 +/- 6 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low salt diet (LSD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High salt diet (HSD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for at least eight weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (AT)
Number of subjects: 10
Study: 8219435

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 3315478

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS) 30 mg/kg
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 304
Study: 31462735

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance
Number of subjects: 88

Group type: COMPARATOR
Intervention: Bendamustine (Benda) induction alone
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: MRD-negative patients at EOI
Number of subjects: 88
Study: 29626045

Group type: EXPERIMENTAL
Intervention: Intervention video (more emotional impact)
Number of subjects: 8353

Group type: COMPARATOR
Intervention: Control video (less emotional impact)
Number of subjects: 8353

Group type: EXPERIMENTAL
Intervention: Intervention video
Number of subjects: 8353

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 8353
Study: 28626765

Group type: EXPERIMENTAL
Intervention: Serum metabolomics profiling using 1H NMR
Number of subjects: 101

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 101
Study: 25764403

Group type: EXPERIMENTAL
Intervention: Videolaryngoscope
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fibreoptic intubation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 100
Study: 23030309

Group type: EXPERIMENTAL
Intervention: Test drug (candesartan cilexetil 16 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reference drug (candesartan cilexetil 16 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both formulations (test and reference)
Number of subjects: 40
Study: 20605254

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1212